- Home
- SLM vs TGTX Comparison
SLM vs TGTX Comparison
Compare SLM & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLM
- TGTX
- Stock Information
- Founded
- SLM 1972
- TGTX 1993
- Country
- SLM United States
- TGTX United States
- Employees
- SLM N/A
- TGTX N/A
- Industry
- SLM Finance: Consumer Services
- TGTX Biotechnology: Pharmaceutical Preparations
- Sector
- SLM Finance
- TGTX Health Care
- Exchange
- SLM Nasdaq
- TGTX Nasdaq
- Market Cap
- SLM 5.9B
- TGTX 5.5B
- IPO Year
- SLM N/A
- TGTX 1995
- Fundamental
- Price
- SLM $28.28
- TGTX $31.33
- Analyst Decision
- SLM Buy
- TGTX Strong Buy
- Analyst Count
- SLM 12
- TGTX 5
- Target Price
- SLM $33.67
- TGTX $48.20
- AVG Volume (30 Days)
- SLM 3.0M
- TGTX 2.0M
- Earning Date
- SLM 10-23-2025
- TGTX 11-03-2025
- Dividend Yield
- SLM 1.84%
- TGTX N/A
- EPS Growth
- SLM N/A
- TGTX N/A
- EPS
- SLM 2.84
- TGTX 2.78
- Revenue
- SLM $1,460,617,000.00
- TGTX $531,898,000.00
- Revenue This Year
- SLM $6.00
- TGTX $82.31
- Revenue Next Year
- SLM $16.24
- TGTX $49.05
- P/E Ratio
- SLM $9.91
- TGTX $11.17
- Revenue Growth
- SLM N/A
- TGTX 100.88
- 52 Week Low
- SLM $23.57
- TGTX $25.28
- 52 Week High
- SLM $34.97
- TGTX $46.48
- Technical
- Relative Strength Index (RSI)
- SLM 58.54
- TGTX 39.54
- Support Level
- SLM $25.95
- TGTX $29.80
- Resistance Level
- SLM $27.12
- TGTX $34.74
- Average True Range (ATR)
- SLM 0.94
- TGTX 1.76
- MACD
- SLM 0.14
- TGTX -0.43
- Stochastic Oscillator
- SLM 57.46
- TGTX 23.21
About SLM SLM Corporation
SLM Corp is an education solutions company. It business is to originate and service loans to students and their families to finance the cost of their education. The provide Private Education Loans to mean education loans to students or their families that are not made, insured, or guaranteed by any state or federal government.
About TGTX TG Therapeutics Inc.
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.